Abstract Background and Objective Amyotrophic lateral sclerosis (ALS) is a progressive
motor and extra‐motor neurodegenerative disease. This systematic review aimed to …

Abstract Amyotrophic Lateral Sclerosis (ALS) is characterized by the degeneration of upper
and lower motor neurons. Clinical heterogeneity is a well‐recognized feature of the disease …

Background Sporadic amyotrophic lateral sclerosis (sALS) is a motor neuron disease with
poorly understood etiology. Results of gene expression profiling studies of whole blood from …

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease and the
proteins and pathways involved in the pathophysiology are not fully understood. Even less is …

Biomarkers research in amyotrophic lateral sclerosis (ALS) holds the promise of improving
ALS diagnosis, follow-up of patients, and clinical trials outcomes. Metabolomics have a big …

Our objective was to identify metabolic pathways affected by ALS using non-targeted
metabolomics in plasma, comparing samples from healthy volunteers to those from ALS …

We use shotgun proteomics to identify biomarkers of diagnostic and prognostic value in
individuals diagnosed with amyotrophic lateral sclerosis. Matched cerebrospinal and …

Background: The clinical diagnosis of ALS is based entirely on clinical features.
Identification of biomarkers for ALS would be important for diagnosis and might also provide …

The lack of biomarkers for early diagnosis, clinical stratification and to monitor treatment
response has hampered the development of new therapies for amyotrophic lateral sclerosis …

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease,
characterized by the progressive loss of lower motor neurons, weakness and muscle …